These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 30457023)

  • 21. Skin and bone: the pathogenetic relationship between psoriasis and psoriatic arthritis.
    Ko JM; Qureshi AW
    G Ital Dermatol Venereol; 2010 Jun; 145(3):393-406. PubMed ID: 20461047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. "Inflammatory skin march" in atopic dermatitis and psoriasis.
    Furue M; Kadono T
    Inflamm Res; 2017 Oct; 66(10):833-842. PubMed ID: 28620798
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ischemic cardiovascular involvement in psoriasis: a systematic review.
    Mosca S; Gargiulo P; Balato N; Di Costanzo L; Parente A; Paolillo S; Ayala F; Trimarco B; Crea F; Perrone-Filardi P
    Int J Cardiol; 2015 Jan; 178():191-9. PubMed ID: 25464252
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis.
    Puig L
    Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29295598
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Psoriasis and cardiovascular disorders.
    Frieder J; Ryan C
    G Ital Dermatol Venereol; 2016 Dec; 151(6):678-693. PubMed ID: 27627099
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular risk factors in high-need psoriasis patients and its implications for biological therapies.
    Driessen RJ; Boezeman JB; Van De Kerkhof PC; De Jong EM
    J Dermatolog Treat; 2009; 20(1):42-7. PubMed ID: 18649164
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Psoriasis and Vascular Risk : An Update.
    Katsiki N; Anagnostis P; Athyros VG; Karagiannis A; Mikhailidis DP
    Curr Pharm Des; 2014; 20(39):6114-25. PubMed ID: 24745923
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiovascular risk and psoriasis: the role of biologic therapy.
    Puig L
    Actas Dermosifiliogr; 2012 Dec; 103(10):853-62. PubMed ID: 23157913
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Double trouble: psoriasis and cardiometabolic disorders.
    Mahyoodeen NG; Crowther NJ; Tikly M
    Cardiovasc J Afr; 2018 May/Jun 23; 29(3):189-194. PubMed ID: 29293257
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study.
    Ahlehoff O; Skov L; Gislason G; Lindhardsen J; Kristensen SL; Iversen L; Lasthein S; Gniadecki R; Dam TN; Torp-Pedersen C; Hansen PR
    J Intern Med; 2013 Feb; 273(2):197-204. PubMed ID: 22963528
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Co-morbidities in psoriasis vulgaris].
    Boehncke WH; Buerger C; Boehncke S
    Hautarzt; 2009 Feb; 60(2):116-21. PubMed ID: 19151962
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolic comorbidities and psoriasis.
    Gisondi P; Ferrazzi A; Girolomoni G
    Acta Dermatovenerol Croat; 2010; 18(4):297-304. PubMed ID: 21251450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Psoriasis and cardiovascular comorbidities with emphasis in Asia.
    Chu TW; Tsai TF
    G Ital Dermatol Venereol; 2012 Apr; 147(2):189-202. PubMed ID: 22481582
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psoriatic disease--from skin to bone.
    Ritchlin C
    Nat Clin Pract Rheumatol; 2007 Dec; 3(12):698-706. PubMed ID: 18037929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Research gaps in psoriasis: opportunities for future studies.
    Ryan C; Korman NJ; Gelfand JM; Lim HW; Elmets CA; Feldman SR; Gottlieb AB; Koo JY; Lebwohl M; Leonardi CL; Van Voorhees AS; Bhushan R; Menter A
    J Am Acad Dermatol; 2014 Jan; 70(1):146-67. PubMed ID: 24126079
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiovascular comorbidities in psoriasis and psoriatic arthritis: pathogenesis, consequences for patient management, and future research agenda: a report from the GRAPPA 2009 annual meeting.
    Boehncke WH; Gladman DD; Chandran V
    J Rheumatol; 2011 Mar; 38(3):567-71. PubMed ID: 21362790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort.
    Ahlehoff O; Skov L; Gislason G; Gniadecki R; Iversen L; Bryld LE; Lasthein S; Lindhardsen J; Kristensen SL; Torp-Pedersen C; Hansen PR
    J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1128-34. PubMed ID: 25303139
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors.
    Miller IM; Ellervik C; Yazdanyar S; Jemec GB
    J Am Acad Dermatol; 2013 Dec; 69(6):1014-24. PubMed ID: 24238156
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Psoriasis: classical and emerging comorbidities.
    Oliveira Mde F; Rocha Bde O; Duarte GV
    An Bras Dermatol; 2015; 90(1):9-20. PubMed ID: 25672294
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients.
    Wakkee M; Thio HB; Prens EP; Sijbrands EJ; Neumann HA
    Atherosclerosis; 2007 Jan; 190(1):1-9. PubMed ID: 16942772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.